These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 323739)

  • 41. Effect of androgen administration on the action of exogenous erythropoietin in hemodialysis patients.
    Sombolos K; Zoumbaridis N; Mavromatidis K; Natse T
    Am J Kidney Dis; 1992 Jan; 19(1):94. PubMed ID: 1739091
    [No Abstract]   [Full Text] [Related]  

  • 42. The clinical effects of recombinant human erythropoietin for the treatment of anemia in end stage renal disease patients on dialysis.
    Uthayanaka Y; Jirajan B; Krairithichai U; Jantavanich N
    Southeast Asian J Trop Med Public Health; 1993 Sep; 24(3):577-82. PubMed ID: 8160072
    [TBL] [Abstract][Full Text] [Related]  

  • 43. [Human recombinant erythropoietin (rH-EPO) in chronic hemodialysis patients].
    Jalil R; Vaccarezza A; Jara A; Lira P; Vial S; Serrano V
    Rev Med Chil; 1990 Jun; 118(6):629-34. PubMed ID: 1775783
    [TBL] [Abstract][Full Text] [Related]  

  • 44. [Use of erythropoietin in patients with chronic renal insufficiency and in hemodialysis].
    Cuero CJ; Pérez Guardia E; de Rivera C
    Rev Med Panama; 1996; 21(1-2):55-9. PubMed ID: 8966240
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Recombinant human erythropoietin in patients with anemia due to end-stage renal disease. US multicenter trials.
    Sobota JT
    Contrib Nephrol; 1989; 76():166-78; discussion 212-8. PubMed ID: 2684519
    [No Abstract]   [Full Text] [Related]  

  • 46. Recombinant human erythropoietin resistance in hemodialysis. Effects of paired filtration dialysis.
    Carozzi S; Nasini MG; Santoni O; Tirotta A; Sanna A
    ASAIO J; 1997; 43(5):M535-8. PubMed ID: 9360100
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Clinical effects of oral fluoxymesterone in patients with dialysis-controlled uremia.
    Lindholm DD; Fisher JW; Vieira JA; Dombeck DH; Bernal G; Lerthora J
    Trans Am Soc Artif Intern Organs; 1973; 19():475-83. PubMed ID: 4722764
    [No Abstract]   [Full Text] [Related]  

  • 48. Managing anemia in dialysis patients: hemoglobin cycling and overshoot.
    Singh AK; Milford E; Fishbane S; Keithi-Reddy SR
    Kidney Int; 2008 Sep; 74(5):679-83. PubMed ID: 18337717
    [No Abstract]   [Full Text] [Related]  

  • 49. Effect of recombinant human erythropoietin on interleukin-1 beta and interleukin-6 in patients on maintenance hemodialysis.
    Sayinalp N; Erdem Y; Haznedaroğlu IC; Dündar S; Cağlar S; Kirazli S
    Clin Nephrol; 1995 Dec; 44(6):404. PubMed ID: 8719556
    [No Abstract]   [Full Text] [Related]  

  • 50. [Clinical studies of recombinant human erythropoietin in patients on long-term dialysis].
    Ji SM; Li LS; Ji DX
    Zhonghua Nei Ke Za Zhi; 1993 Feb; 32(2):100-2. PubMed ID: 8404323
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Correction of hemodialysis anemia is associated with significant increase in serum concentration of IGF-I in patients treated with erythropoietin: a randomized controlled study.
    Sheashaa HA; Khalil A; Aarman MM; El-Shahat FB; Selim A; El-Gawad SS
    Int Urol Nephrol; 2005; 37(1):153-8. PubMed ID: 16132779
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Chapter 8 Haemoglobin, ferritin and erythropoietin amongst UK adult dialysis patients in 2010: national and centre-specific analyses.
    Webb L; Gilg J; Wilkie M
    Nephron Clin Pract; 2012; 120 Suppl 1():c145-74. PubMed ID: 22964566
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Understanding epoetin use: databases or clinical trials?
    Roger SD
    Nephrology (Carlton); 2007 Apr; 12(2):118-9. PubMed ID: 17371331
    [No Abstract]   [Full Text] [Related]  

  • 54. Effect on hemoglobin F synthesis by erythropoietin in patients with anemia of end-stage renal disease maintained by chronic hemodialysis.
    Salvati F; Strippoli P; Barchetti M; Scatizzi A
    Nephron; 1992; 60(3):371. PubMed ID: 1373475
    [No Abstract]   [Full Text] [Related]  

  • 55. Target hemoglobin level for EPO therapy in CKD.
    Parfrey PS
    Am J Kidney Dis; 2006 Jan; 47(1):171-3. PubMed ID: 16377399
    [No Abstract]   [Full Text] [Related]  

  • 56. [Human recombinant erythropoietin in the treatment of anemia in patients on long-term hemodialysis].
    Boratyńska M; Szewczyk Z; Szepietowski T; Czyz W; Cybulski K; Bogucki J; Szczepański J
    Przegl Lek; 1990; 47(11):741-5. PubMed ID: 2098840
    [TBL] [Abstract][Full Text] [Related]  

  • 57. [Effect of recombinant human erythropoietin on the bone marrow picture in patients with chronic renal failure treated by hemodialysis].
    Sułowicz W; Hanicki Z; Skotnicki AB; Wójcik J; Sydor A
    Przegl Lek; 1992; 49(3):88-90. PubMed ID: 1438902
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Morbidity and mortality in hemodialysis patients with and without erythropoietin treatment: a controlled study.
    Bahlmann J; Schöter KH; Scigalla P; Gurland HJ; Hilfenhaus M; Koch KM; Muthny FA; Neumayer HH; Pommer W; Quelhorst E
    Contrib Nephrol; 1991; 88():90-106. PubMed ID: 2040200
    [No Abstract]   [Full Text] [Related]  

  • 59. Anemia Evaluation and Erythropoietin Dose Requirement Among Hemodialysis Patients: a Multicenter Study.
    Nafar M; Samavat S; Khoshdel A; Alipour-Abedi B
    Iran J Kidney Dis; 2017 Jan; 11(1):56-65. PubMed ID: 28174354
    [TBL] [Abstract][Full Text] [Related]  

  • 60. The effective use of nandrolone decanoate in the management of the anemia of uremia: a prospective study.
    Armitage JO; Leighton M; Ware F
    Nebr Med J; 1976 Jun; 61(6):202-6. PubMed ID: 1272455
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.